BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
USA - NASDAQ:BMRN - US09061G1013 - Common Stock
53.37 USD
-0.44 (-0.82%)
53.37 USD
0 (0%)
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BMRN may be a bit undervalued, certainly considering the very reasonable score on growth This makes BMRN very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
In the past year BMRN had a positive cash flow from operations.
BMRN had positive earnings in 4 of the past 5 years.
In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 8.81%, BMRN belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
The Return On Equity of BMRN (10.90%) is better than 93.45% of its industry peers.
The Return On Invested Capital of BMRN (10.27%) is better than 94.38% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BMRN is significantly below the industry average of 15.49%.
The last Return On Invested Capital (10.27%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROIC | 10.27% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
BMRN's Profit Margin of 21.45% is amongst the best of the industry. BMRN outperforms 94.76% of its industry peers.
Looking at the Operating Margin, with a value of 27.07%, BMRN belongs to the top of the industry, outperforming 96.07% of the companies in the same industry.
BMRN's Gross Margin of 79.56% is amongst the best of the industry. BMRN outperforms 84.83% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BMRN is creating some value.
BMRN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BMRN has been increased compared to 5 years ago.
BMRN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.66 indicates that BMRN is not in any danger for bankruptcy at the moment.
The Altman-Z score of BMRN (5.66) is better than 74.53% of its industry peers.
BMRN has a debt to FCF ratio of 0.86. This is a very positive value and a sign of high solvency as it would only need 0.86 years to pay back of all of its debts.
BMRN has a better Debt to FCF ratio (0.86) than 94.76% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 63.86% of its industry peers.
Even though the debt/equity ratio score it not favorable for BMRN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Altman-Z | 5.66 |
ROIC/WACC1.14
WACC9.03%
2.3 Liquidity
A Current Ratio of 5.56 indicates that BMRN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.56, BMRN is in line with its industry, outperforming 59.93% of the companies in the same industry.
BMRN has a Quick Ratio of 3.60. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
BMRN has a Quick ratio of 3.60. This is comparable to the rest of the industry: BMRN outperforms 44.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 139.01% over the past year.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 18.36% in the last year.
BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.62% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.60% yearly.
EPS Next Y59.45%
EPS Next 2Y43.31%
EPS Next 3Y34.04%
EPS Next 5Y28.62%
Revenue Next Year12.48%
Revenue Next 2Y10.82%
Revenue Next 3Y9.76%
Revenue Next 5Y7.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.84, the valuation of BMRN can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 96.44% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.57, BMRN is valued a bit cheaper.
With a Price/Forward Earnings ratio of 11.76, the valuation of BMRN can be described as very reasonable.
96.82% of the companies in the same industry are more expensive than BMRN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.09. BMRN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.84 | ||
| Fwd PE | 11.76 |
4.2 Price Multiples
96.44% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
96.44% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.83 | ||
| EV/EBITDA | 10.17 |
4.3 Compensation for Growth
BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 34.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.27
PEG (5Y)N/A
EPS Next 2Y43.31%
EPS Next 3Y34.04%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
53.37
-0.44 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change0.05%
Ins Owners0.65%
Ins Owner Change1.95%
Market Cap10.25B
Revenue(TTM)3.06B
Net Income(TTM)657.24M
Analysts83.53
Price Target97.37 (82.44%)
Short Float %3.84%
Short Ratio3.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.96%
Min EPS beat(2)31.48%
Max EPS beat(2)44.44%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)4.22%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)18.75%
EPS beat(12)9
Avg EPS beat(12)-3.48%
EPS beat(16)13
Avg EPS beat(16)0.88%
Revenue beat(2)1
Avg Revenue beat(2)2.55%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)6.48%
Revenue beat(4)3
Avg Revenue beat(4)3.05%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.05%
Revenue beat(12)5
Avg Revenue beat(12)0.21%
Revenue beat(16)7
Avg Revenue beat(16)-0.31%
PT rev (1m)-0.83%
PT rev (3m)-0.06%
EPS NQ rev (1m)9.51%
EPS NQ rev (3m)-22.53%
EPS NY rev (1m)0.99%
EPS NY rev (3m)0.1%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)-1.89%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.97%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.84 | ||
| Fwd PE | 11.76 | ||
| P/S | 3.34 | ||
| P/FCF | 14.83 | ||
| P/OCF | 13.36 | ||
| P/B | 1.7 | ||
| P/tB | 1.83 | ||
| EV/EBITDA | 10.17 |
EPS(TTM)3.37
EY6.31%
EPS(NY)4.54
Fwd EY8.5%
FCF(TTM)3.6
FCFY6.74%
OCF(TTM)3.99
OCFY7.48%
SpS15.96
BVpS31.39
TBVpS29.12
PEG (NY)0.27
PEG (5Y)N/A
Graham Number48.79
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 10.9% | ||
| ROCE | 12.25% | ||
| ROIC | 10.27% | ||
| ROICexc | 13.02% | ||
| ROICexgc | 14.18% | ||
| OM | 27.07% | ||
| PM (TTM) | 21.45% | ||
| GM | 79.56% | ||
| FCFM | 22.56% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score7
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.86 | ||
| Debt/EBITDA | 0.65 | ||
| Cap/Depr | 90.83% | ||
| Cap/Sales | 2.47% | ||
| Interest Coverage | 93.49 | ||
| Cash Conversion | 84.01% | ||
| Profit Quality | 105.16% | ||
| Current Ratio | 5.56 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | 5.66 |
F-Score7
WACC9.03%
ROIC/WACC1.14
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)139.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%119.64%
EPS Next Y59.45%
EPS Next 2Y43.31%
EPS Next 3Y34.04%
EPS Next 5Y28.62%
Revenue 1Y (TTM)18.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%15.92%
Revenue Next Year12.48%
Revenue Next 2Y10.82%
Revenue Next 3Y9.76%
Revenue Next 5Y7.6%
EBIT growth 1Y198.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.49%
EBIT Next 3Y41.32%
EBIT Next 5Y23.56%
FCF growth 1Y1589.89%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.67%
OCF growth 3Y23.45%
OCF growth 5Y63.99%